JP2019503984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503984A5 JP2019503984A5 JP2018521955A JP2018521955A JP2019503984A5 JP 2019503984 A5 JP2019503984 A5 JP 2019503984A5 JP 2018521955 A JP2018521955 A JP 2018521955A JP 2018521955 A JP2018521955 A JP 2018521955A JP 2019503984 A5 JP2019503984 A5 JP 2019503984A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- dkk2
- subject
- antibody
- humanized anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562247410P | 2015-10-28 | 2015-10-28 | |
| US62/247,410 | 2015-10-28 | ||
| PCT/US2016/057814 WO2017074774A1 (en) | 2015-10-28 | 2016-10-20 | Humanized anti-dkk2 antibody and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019503984A JP2019503984A (ja) | 2019-02-14 |
| JP2019503984A5 true JP2019503984A5 (https=) | 2019-11-28 |
| JP6921067B2 JP6921067B2 (ja) | 2021-08-18 |
Family
ID=58630689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521955A Active JP6921067B2 (ja) | 2015-10-28 | 2016-10-20 | ヒト化抗Ｄｋｋ２抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11267875B2 (https=) |
| EP (1) | EP3368567B1 (https=) |
| JP (1) | JP6921067B2 (https=) |
| KR (1) | KR20180085723A (https=) |
| CN (1) | CN108463247B (https=) |
| AU (1) | AU2016344459B2 (https=) |
| CA (1) | CA3003252C (https=) |
| DK (1) | DK3368567T3 (https=) |
| IL (1) | IL258924A (https=) |
| RU (1) | RU2018119317A (https=) |
| WO (1) | WO2017074774A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3368567B1 (en) | 2015-10-28 | 2025-10-01 | Yale University | Humanized anti-dkk2 antibody and uses thereof |
| EP3835321A4 (en) | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| CA3128526A1 (en) | 2019-02-01 | 2020-08-06 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
| EP3693063A1 (en) * | 2019-02-06 | 2020-08-12 | Diaccurate | Methods and compositions for treating cancer |
| WO2021003687A1 (en) * | 2019-07-10 | 2021-01-14 | Yale University | Compositions and methods of using a humanized anti-dkk2 antibody |
| TWI895351B (zh) * | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6133232A (en) | 1996-06-20 | 2000-10-17 | The Regents Of The University Of California | Endoderm, cardiac and neural inducing factors |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| US7057017B2 (en) * | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DK1390535T3 (da) | 2001-04-26 | 2010-12-06 | Amgen Mountain View Inc | Kombinatoriske biblioteker af monomer-domæner |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| AU2002357932A1 (en) | 2001-12-18 | 2003-06-30 | Whitehead Institute For Biomedical Research | Fusion partner cells and uses thereof |
| ES2350687T3 (es) * | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| KR100781753B1 (ko) * | 2006-05-24 | 2007-12-04 | 연세대학교 산학협력단 | Ｄｋｋ2를 포함하는 혈관신생을 촉진시키는 방법 |
| JP2013529076A (ja) * | 2010-05-11 | 2013-07-18 | アベオ ファーマシューティカルズ， インコーポレイテッド | 抗ｆｇｆｒ２抗体 |
| CN103608037B (zh) * | 2011-02-01 | 2016-04-13 | 香港大学 | 抗dkk1单克隆抗体用于治疗肝癌的用途 |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| KR101508052B1 (ko) * | 2013-05-20 | 2015-04-08 | 울산대학교 산학협력단 | 생물학적 활성을 가진 인간 Ｄｋｋ２ 재조합 단백질의 수용성 발현 및 정제방법 |
| EP3978524A1 (en) | 2014-07-03 | 2022-04-06 | Yale University | Dickkopf2 (dkk2) inhibition suppresses tumor formation |
| US11078278B2 (en) * | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| EP3368567B1 (en) | 2015-10-28 | 2025-10-01 | Yale University | Humanized anti-dkk2 antibody and uses thereof |
-
2016
- 2016-10-20 EP EP16860530.1A patent/EP3368567B1/en active Active
- 2016-10-20 KR KR1020187013788A patent/KR20180085723A/ko not_active Ceased
- 2016-10-20 WO PCT/US2016/057814 patent/WO2017074774A1/en not_active Ceased
- 2016-10-20 JP JP2018521955A patent/JP6921067B2/ja active Active
- 2016-10-20 AU AU2016344459A patent/AU2016344459B2/en active Active
- 2016-10-20 RU RU2018119317A patent/RU2018119317A/ru not_active Application Discontinuation
- 2016-10-20 CN CN201680075535.2A patent/CN108463247B/zh active Active
- 2016-10-20 CA CA3003252A patent/CA3003252C/en active Active
- 2016-10-20 DK DK16860530.1T patent/DK3368567T3/da active
- 2016-10-20 US US15/771,965 patent/US11267875B2/en active Active
-
2018
- 2018-04-25 IL IL258924A patent/IL258924A/en unknown
-
2022
- 2022-02-07 US US17/666,018 patent/US20220162294A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503984A5 (https=) | ||
| Dhanyamraju et al. | Melanoma therapeutics: a literature review | |
| US20250177494A1 (en) | Methods of cytotoxic gene therapy to treat tumors | |
| Kamran et al. | Current state and future prospects of immunotherapy for glioma | |
| US20210299187A1 (en) | Cancer therapy | |
| CN107073099B (zh) | 用于治疗癌症的联合方法 | |
| JP7200093B2 (ja) | がん治療用ｔｌｒ９アゴニストを用いた免疫調節 | |
| Almquist et al. | The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma: DR Almquist et al. | |
| RU2018119317A (ru) | Гуманизированное антитело к dkk2 и его применение | |
| JP2017527533A5 (https=) | ||
| JP6892443B2 (ja) | がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム | |
| Afolabi et al. | Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat | |
| Alsina et al. | Immunotherapy of esophageal cancer: current status, many trials and innovative strategies | |
| Ostios-Garcia et al. | Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| WO2020146345A1 (en) | Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy | |
| Misra et al. | Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective | |
| Dovedi et al. | Emerging targeted therapies for bladder cancer: a disease waiting for a drug | |
| KR20210106531A (ko) | 암 치료를 위한 조성물 및 방법 | |
| Li et al. | Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade | |
| Crombet Ramos et al. | The position of EGF deprivation in the management of advanced non-small cell lung cancer | |
| JP2021502344A (ja) | 腫瘍を処置する方法 | |
| WO2019094352A1 (en) | Inhibition of ctla-4 and/or pd-1 for regulation of t cells | |
| Lenzen et al. | Immu-01. Novel rna-targeting strategy for treating T cell-driven immunosuppression in human diffuse intrinsic pontine glioma | |
| JP7407452B2 (ja) | がんの治療及び／又は予防のための医薬 |